Company news
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) news
Mineralys Therapeutics, Inc. news releases on 6ix. Latest, Oct 2, 2026: Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American…
Press releases & updates
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
October 2, 2026
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
October 1, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 28, 2026
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
September 24, 2026
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
September 23, 2026
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
August 26, 2026
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
August 4, 2026
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
June 14, 2026
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
June 8, 2026
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
June 3, 2026
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
June 3, 2026
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
May 29, 2026
Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 27, 2026
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
May 18, 2026
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
April 29, 2026
Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors
April 6, 2026
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
March 23, 2026
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
March 12, 2026
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
March 8, 2026
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
March 8, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2026
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
January 5, 2026
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
December 11, 2025
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
November 25, 2025
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 9, 2025
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
November 6, 2025
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
November 4, 2025
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
November 2, 2025
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
October 20, 2025
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
September 29, 2025
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
September 5, 2025
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
September 4, 2025
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 3, 2025
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
September 1, 2025
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
September 1, 2025
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 11, 2025
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025
August 3, 2025
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
June 29, 2025
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
June 16, 2025
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
May 23, 2025
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
May 19, 2025
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 11, 2025
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
May 6, 2025
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025
May 4, 2025
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
April 22, 2025
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)
March 28, 2025
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
March 24, 2025
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
March 17, 2025